Grants per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Pharmacology & Biomedical Sciences, PhD, University of Portsmouth
… → 2020
Medicine, MD, Bangalore Medical College, India
… → 2010
Fingerprint
Dive into the research topics where Niraj K Shenoy is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Grants
- 3 Active
-
Enhancing the Efficacy of Immunotherapy in Cancer with Ascorbic Acid
Shenoy, N. K. (PD/PI), Shenoy, N. K. (PD/PI), Luchtel, R. A. (Co-Investigator) & Luchtel, R. A. (Co-Investigator)
Lotte and John Hecht Memorial Foundation
4/1/22 → 12/31/25
Project: Research project
-
Epigenetic Targeting of Clear Cell Renal Cell Carcinoma
Shenoy, N. K. (PD/PI), Shenoy, N. K. (PD/PI), Shenoy, N. K. (PD/PI), Luchtel, R. A. (Co-Investigator), Luchtel, R. A. (Co-Investigator) & Luchtel, R. A. (Co-Investigator)
1/1/21 → 6/30/25
Project: Research project
-
Prot #MK-3475-426: A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcin
Carneiro Filho, B. A. (PD/PI), Shenoy, N. K. (PD/PI), Sosman, J. A. (PD/PI), Sosman, J. A. (PD/PI) & Carneiro Filho, B. A. (Other)
DrugDev Inc., Merck Sharp & Dohme Corporation
2/22/17 → 2/28/26
Project: Research project
-
Considerations in Meta-Analysis of Immunotherapy for Advanced Cancers Other Than Melanoma - Reply
Shenoy, N. K., Apr 18 2024, In: JAMA Oncology. 10, 4, p. 536 1 p.Research output: Contribution to journal › Letter › peer-review
-
Derivative survival analyses: Analysis methods to derive survival outcomes for the remainder patient cohort without individual patient data
Shenoy, N. K., Apr 16 2024, In: Cell Reports Medicine. 5, 4, 101500.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Neurological applications of belzutifan in von Hippel-Lindau disease
Zhang, Y., Nguyen, C. C., Zhang, N. T., Fink, N. S., John, J. D., Venkatesh, O. G., Roe, J. D., Hoffman, S. C., Lesniak, M. S., Wolinsky, J. P., Horbinski, C., Szymaniak, B. M., Buerki, R. A., Sosman, J. A., Shenoy, N. K. & Lukas, R. V., May 1 2023, In: Neuro-oncology. 25, 5, p. 827-838 12 p.Research output: Contribution to journal › Review article › peer-review
Open Access13 Scopus citations -
Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis
Serritella, A. V. & Shenoy, N. K., Oct 19 2023, In: JAMA Oncology. 9, 10, p. 1441-1446 6 p.Research output: Contribution to journal › Article › peer-review
Open Access20 Scopus citations -
Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer
Aggarwal, R. K., Luchtel, R. A., Machha, V., Tischer, A., Zou, Y., Pradhan, K., Ashai, N., Ramachandra, N., Albanese, J. M., Yang, J. I., Wang, X., Aluri, S., Gordon, S., Aboumohamed, A., Gartrell, B. A., Hafizi, S., Pullman, J. & Shenoy, N., Sep 28 2021, In: Proceedings of the National Academy of Sciences of the United States of America. 118, 39, e2106947118.Research output: Contribution to journal › Article › peer-review
Open Access44 Scopus citations